CH634574A5 - Verfahren zur herstellung von 7-(2,3-dihydroxypropyl)-1,3-di-n-propylxanthin. - Google Patents
Verfahren zur herstellung von 7-(2,3-dihydroxypropyl)-1,3-di-n-propylxanthin. Download PDFInfo
- Publication number
- CH634574A5 CH634574A5 CH494277A CH494277A CH634574A5 CH 634574 A5 CH634574 A5 CH 634574A5 CH 494277 A CH494277 A CH 494277A CH 494277 A CH494277 A CH 494277A CH 634574 A5 CH634574 A5 CH 634574A5
- Authority
- CH
- Switzerland
- Prior art keywords
- compound
- propylxanthine
- dose
- theophylline
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C07D239/62—Barbituric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/680,936 US4031218A (en) | 1976-04-28 | 1976-04-28 | 7-(2,3-Dihydroxypropyl-1,3-di-n-propylxanthine and a pharmaceutical composition containing same useful as a bronchial muscle relaxant |
Publications (1)
Publication Number | Publication Date |
---|---|
CH634574A5 true CH634574A5 (de) | 1983-02-15 |
Family
ID=24733117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH494277A CH634574A5 (de) | 1976-04-28 | 1977-04-21 | Verfahren zur herstellung von 7-(2,3-dihydroxypropyl)-1,3-di-n-propylxanthin. |
Country Status (10)
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4221910A (en) * | 1978-09-15 | 1980-09-09 | Newport Pharmaceuticals International, Inc. | 9-(Hydroxy alkyl)purines |
US4368197A (en) * | 1979-02-21 | 1983-01-11 | Research Corporation | Zinc aminophylline and its use in the treatment of bronchospasms |
DE3133553A1 (de) * | 1981-08-25 | 1983-03-10 | Degussa Ag, 6000 Frankfurt | Verfahren zur herstellung von dihydroxypropyltheophyllin |
DE3138397A1 (de) * | 1981-09-26 | 1983-04-07 | Hoechst Ag, 6230 Frankfurt | "arzneimittel, darin enthaltene vicinale dihydroxyalkylxanthine und herstellungsverfahren fuer diese xanthinverbindungen" |
US4581359A (en) * | 1984-04-23 | 1986-04-08 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University | Pharmacological treatments with N-7-substituted derivatives of theophylline |
US4663326A (en) * | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4755517A (en) * | 1986-07-31 | 1988-07-05 | Warner-Lambert Company | Derivatives of xanthine, pharmaceutical compositions and methods of use therefor |
FR2611716A1 (fr) * | 1987-03-06 | 1988-09-09 | Uriach Cia Sa J | Derives de diisobutylxanthine substituee en position 7 utiles comme bronchodilatateurs, procede pour leur preparation et composition pharmaceutique les contenant |
US5288721A (en) * | 1992-09-22 | 1994-02-22 | Cell Therapeutics, Inc. | Substituted epoxyalkyl xanthines |
US5981549A (en) * | 1997-02-14 | 1999-11-09 | Synapse Pharmaceutical International | Method for controlling or alleviating the symptoms of respiratory disease and allergies |
US6313131B1 (en) | 1999-02-16 | 2001-11-06 | Upsher-Smith Laboratories, Inc. | Method of kidney treatment |
US6423719B1 (en) | 1999-02-16 | 2002-07-23 | Upsher-Smith Laboratories, Inc. | Method for treating benign prostate hyperplasia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2756229A (en) * | 1956-07-24 | Xanthine derivatives | ||
US2517410A (en) * | 1947-08-15 | 1950-08-01 | Searle & Co | Hydroxy alkyl xanthines and the production thereof |
-
1976
- 1976-04-28 US US05/680,936 patent/US4031218A/en not_active Expired - Lifetime
-
1977
- 1977-03-31 GB GB13631/77A patent/GB1521237A/en not_active Expired
- 1977-04-13 DE DE19772716402 patent/DE2716402A1/de not_active Withdrawn
- 1977-04-21 CH CH494277A patent/CH634574A5/de not_active IP Right Cessation
- 1977-04-25 CA CA276,842A patent/CA1082184A/en not_active Expired
- 1977-04-27 BE BE177045A patent/BE853990A/xx unknown
- 1977-04-27 FR FR7712802A patent/FR2349585A1/fr active Granted
- 1977-04-27 NL NL7704585A patent/NL7704585A/xx not_active Application Discontinuation
- 1977-04-28 JP JP4861677A patent/JPS52148097A/ja active Granted
- 1977-04-28 SE SE7704944A patent/SE7704944L/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JPS5416518B2 (US06265458-20010724-C00056.png) | 1979-06-22 |
US4031218A (en) | 1977-06-21 |
SE7704944L (sv) | 1977-10-29 |
FR2349585B1 (US06265458-20010724-C00056.png) | 1980-04-04 |
JPS52148097A (en) | 1977-12-08 |
GB1521237A (en) | 1978-08-16 |
DE2716402A1 (de) | 1977-11-10 |
BE853990A (fr) | 1977-08-16 |
NL7704585A (nl) | 1977-11-01 |
FR2349585A1 (fr) | 1977-11-25 |
CA1082184A (en) | 1980-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE2904445C2 (de) | N↓1↓-(4-Amino-6.7-dimethoxy-2-chinazolyl)-N↓1↓-methyl-N↓2↓-(2-tetrahydrofuroyl)-1.3-propandiamin, seine Herstellung und seine pharmazeutische Verwendung | |
DE69132389T2 (de) | 2-aralkoxy und 2-alkoxy-adenosinderivate als koronarvasodilatoren und antihypertensive stoffe | |
DD146708A5 (de) | Verfahren zur herstellung von 3-alkylxanthinen | |
DE69107215T2 (de) | (2-imidazolin-2-ylamino)chinoxalinderivate und methoden in ihrer anwendung. | |
DE2462367A1 (de) | 7-(oxoalkyl)-1,3-dialkylxanthine enthaltende arzneimittelzubereitungen | |
DD139855A5 (de) | Verfahren zur herstellung von xanthinderivaten | |
CH634574A5 (de) | Verfahren zur herstellung von 7-(2,3-dihydroxypropyl)-1,3-di-n-propylxanthin. | |
DE2713389C2 (US06265458-20010724-C00056.png) | ||
DE3717080C2 (de) | 1-(Hydroxystyryl)-5H-2,3-benzodiazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
DE19602964A1 (de) | Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung | |
DE69412073T2 (de) | Xanthinderivate als adenosin-a1 rezeptor antagonisten | |
DE2403122C2 (US06265458-20010724-C00056.png) | ||
CH615410A5 (en) | Process for the preparation of novel alpha-ethylbenzhydrol derivatives | |
DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
DE69919478T2 (de) | 7-Aminopyrido(2,3-d)-pyrimidine Derivate zur Behandlung von Bronchialasthma | |
DE2451360C2 (de) | 9-Hydroxyellipticin, Verfahren zu dessen Herstellung und seine Verwendung als Arzneimittel | |
EP0812844A2 (de) | Verwendung von Theophyllinderivaten zur Behandlung und Propylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung | |
CH643862A5 (de) | Bis(4-demethoxydaunorubicin)dihydrazon-derivate und sie enthaltende pharmazeutische zubereitungen. | |
EP0024258A1 (de) | Die Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Herpes-Infektionen | |
EP0032564A1 (de) | Pharmazeutische Verwendung von Caroverin und/oder Caroverinsalzen sowie Caroverinsalze mit Xanthinderivat-Säureresten und Nicotinsäurerest | |
DE3212909C2 (US06265458-20010724-C00056.png) | ||
DE2427208A1 (de) | Triazole und deren salze, verfahren zu deren herstellung und sie enthaltende arzneimittel | |
DE2355536A1 (de) | Adeninderivate und verfahren zu ihrer herstellung | |
DE60026559T2 (de) | Arzneimittel gegen essstörungen | |
DE2749075A1 (de) | Quaternaere 1-methyl-2-(phenothiazin- 10-yl)-aethylammoniumsalze und diese enthaltende arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |